Cancer survival is rising, but not for everyone

2 September 2025

For decades, a cancer diagnosis was often seen as a death sentence. Today, survival is steadily improving, thanks to advances in science, medicine, and public health. Yet the gains are uneven, leaving some cancers, and some patients, far behind.

A half-century of progress

In the 1970s, only half of cancer patients in the USA survived five years beyond diagnosis. That figure has now climbed to nearly 70%. In England and Wales, half of all patients now live for at least ten years, double the rate in the early 1970s.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Pharmaceutical